Studying how a kidney-protecting pathway works in ADPKD
Part of Genetic & congenital, Kidney & urinary, Women’s health & pregnancy clinical trials.
This study looks at how the body’s “Nrf2 response” works in people with autosomal dominant polycystic kidney disease (ADPKD). It may help researchers better understand disease biology and future treatments by comparing kidney-related signals in ADPKD patients and healthy volunteers.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You (or the study group you’re joining) must be age 18 to 30
- If you have ADPKD: you must meet specific scan-based disease severity class 1 (not class 2)
- Your kidney function must be good (estimated GFR above 60)
- You must not have diabetes or high blood sugar based on lab or diabetes medicines
- Urine test results should not show high protein (more than 1 gram per day) or signs of other kidney “filter” disease
- You must be able to have MRI scans safely (for example, no certain metal implants, and you shouldn’t be pregnant)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study measures a kidney-related marker (NOX4) and other blood/urine signals in people with early-stage ADPKD to better understand disease activity. It may help researchers identify who is likely to progress and why, though it may not be a treatment study.
This trial tests a new study drug called AZD1613 for adults with a certain type of kidney disease (ADPKD). Researchers want to see if it is safe, how the body handles it, and what the right dose might be.
This study collects samples and health information from adults with autosomal dominant polycystic kidney disease (ADPKD) who are having their own kidney removed. It helps researchers learn more about ADPKD and its genetic changes to support future treatments.
This study enrolls adults with autosomal dominant polycystic kidney disease (ADPKD) to better understand the disease and its related changes in the body. It may help researchers find improved ways to track the condition and support future treatments.
This observational study follows people early in autosomal dominant polycystic kidney disease (ADPKD) and also some healthy volunteers to learn how the kidneys work over time. It may help researchers understand early changes, which could guide future treatments.
This study looks at people with autosomal dominant polycystic kidney disease to learn more about the condition. It is an observational study, meaning no new treatments are tested—just gathering information from your medical history and tests.
Hear when a new Autosomal Dominant Polycystic Kidney Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.